U.S. Markets close in 3 hrs 40 mins

Class Action Reminder GSM, TYME & LXRX - Bronstein, Gewirtz & Grossman, LLC

NEW YORK, March 21, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Ferroglobe PLC (GSM) 
Class Period: August 21, 2018 - November 26, 2018
Lead Plaintiff Deadline: March 25, 2019
For more info: www.bgandg.com/gsm

The Complaint alleges that throughout the Class Period Defendants made materially false and misleading statements and/or failed to disclose that: (1) that there was excess supply of the Company’s products; (2) that demand for the Company’s products was declining; (3) that, as a result, the pricing of the Company’s products would be materially impacted; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Tyme Technologies, Inc. (TYME) 
Class Period:
March 14, 2018 - January 18, 2019
Lead Plaintiff Deadline: March 29, 2019
For more info: www.bgandg.com/tyme

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) Tyme had not adequately designed the Phase II Study to present reliable results on the efficacy of SM-88 on pancreatic cancer; (2) Tyme had failed to include an appropriate control group in its open-label Phase II clinical trial for SM-88; (3) the omission of an appropriate control group distorted the reliability of data showing the efficacy of SM-88 in the Phase II Study; and (4) as a result, Tyme’s public statements were materially false and misleading at all relevant times.

Lexicon Pharmaceuticals, Inc. (LXRX) 
Class Period: March 11, 2016 - January 17, 2019
Lead Plaintiff Deadline: April 1, 2019
For more info: www.bgandg.com/lxrx.

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) the data from Lexicon’s Phase 3 clinical trials assessing the safety and efficacy of Sotagliflozin in treating type 1 diabetes were not as positive as Lexicon represented; (2) the health risks posed by Sotagliflozin were severe enough to threaten its FDA approval prospects; and (3) as a result, Lexicon’s public statements were materially false and misleading at all relevant times.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com